We counted unique claims with a Current Procedural Terminology code of 65855 (LTP) submitted by ophthalmologists, optometrists, ambulatory surgery centers, or outpatient hospitals by region for each year. We examined trends over time and regional variation in LTP rates in 9 large geographic regions. 
S ince its introduction into clinical care for open-angle glaucoma (OAG) in the 1980s, laser trabeculoplasty (LTP) has remained an important component of glaucoma therapy, along with medical treatment and incisional surgery. Laser trabeculoplasty was estimated to have been performed in about 5% of Medicare beneficiaries with a coded diagnosis of OAG in 2009, comprising 7% of the total payments for OAG care to beneficiaries in that year. 1 Ramulu et al 2 and Schmier et al 3 reported on trends over time in the rate of LTP in the United States, noting that rates decreased between 1996 and 2001 and then more than doubled between 2001 and 2006. They speculated that this turnaround might be related to the advent of a new technology, selective laser trabeculoplasty (SLT), and/or to widening of the indications for LTP. The precise role of LTP in the management of glaucoma remains unclear. As with other chronic conditions, 4 ophthalmologists may adopt their own practice style that can be influenced by factors other than the characteristics of their particular patient population. 5 Large geographic variation in medical and surgical care may imply overuse or underuse, 6 although objective standards are not available to assess the appropriateness of use rates in most medical procedures. Previous ophthalmic research has documented geographic variation in the performance of cataract surgery, 7, 8 preoperative gonioscopy, 9 visual field testing, 10 type of retinal detachment repair, 11 and the diagnosis of glaucoma. 12 Medicare billing data permit the study of large numbers of patients who are representative of the elderly US population. In this investigation, we examined whether the increase in LTP noted between 2001 and 2006 continued in the next 3 years and if regional variations existed in using LTP to treat glaucoma.
Methods
The research protocol was approved by the Privacy Board at the Centers for Medicare & Medicaid Services. The Johns Hopkins University School of Medicine and Wake Forest School of Medicine Institutional Review Boards determined that this study qualified for an exemption from institutional review board review and oversight. Statistical analyses were performed using SAS, version 9.3, of the SAS System for Unix (SAS Institute, Inc).
Data Source
We obtained 5% Medicare research-identifiable files for 2002 through 2009 from the Research Data Distribution Center at the Centers for Medicare & Medicaid Services. These files contain a 5% random sample of all Medicare beneficiaries' information on payment for health care services provided by Medicare in the fee-for-service sector. Files obtained included the carrier (formerly physician or supplier Part B file), outpatient facility, and denominator or beneficiary summary files for each year. Claims files contain information on dates and place of service; International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) diagnosis and Current Procedural Terminology (CPT) procedure codes; provider identifier numbers for the provider submitting the claim; provider type (eg, ophthalmologist or optometrist); billing codes and associated charges; and payments. In addition to individual provider claims, the carrier file also contains facility claims from ambulatory surgery centers.
The denominator files provide demographic and residence information and Medicare eligibility status for all beneficiaries in the 5% sample. We limited each yearly denominator file to beneficiaries from one of the 50 states or the District of Columbia who were 65 years or older with continuous Part B eligibility and no health maintenance organization enrollment in that year. Beneficiaries with partial-year eligibility, either due to death or enrollment after January of that year, were also included, with the person-years adjusted to account for the amount of time that they were enrolled. The number of beneficiary personyears was calculated by summing the amount of time that each beneficiary contributed for a given year.
LTP Treatments
All claims with a CPT code of 65855 (LTP) were extracted from the carrier and outpatient facility files for each calendar year. Claims for postoperative management only (modifier code 55) were deleted. Professional fee claims, supplemented by information from facility fee claims, were used to classify each treatment as unilateral or bilateral using procedure modifier codes. Bilateral treatments on the same visit day were counted as 2 treated eyes. Total number of treated eyes was summed for every beneficiary for each calendar year. We estimated the total number of LTPs per year nationally in this population by multiplying the number of claims in our 5% sample by 20. Data were examined to determine the number of LTP re-treatments each patient received, as well as the number of LTP re-treatments per eye.
Categorization of Glaucoma Diagnosis
Carrier claims from each year were used to categorize patients by type of glaucoma as previously described. 12 
Annual Rates of LTP Treatment
The annual LTP rate per 10 000 Medicare beneficiary personyears was calculated by dividing the total number of treated eyes by the total number of beneficiary person-years for each year from 2002 through 2009 and multiplying by 10 000. Rates per 10 000 person-years also were calculated separately for patients diagnosed with OAG-s and OAG. The 95% CIs were calculated for all rates using generalized linear models with a test for trend to compare mean LTP rates over time.
Results
The estimated total number of LTPs performed in all aged Medicare beneficiaries receiving care in the fee-for-service sector Among patients with a diagnostic code for OAG, regional differences were evident in the frequency of LTP use throughout the period studied. In 2002, rates per 10 000 OAG personyears ranged from 314 in the East South-Central region to 607 in the East North-Central region (a 1.9-fold difference; P < .001) ( Figure 4A ). In general, the increase in the rate of LTP be- In 92.4% of eyes, we could ascertain the laterality of treatment. Among those eyes, 78.9% received a single LTP during the study period, 16.6% had 2 LTPs, 3.2% had 3, and 1.3% had 4 or more LTPs.
Discussion
We report that the use of a therapeutic procedure, LTP, increased dramatically in the Medicare population between 2002 and 2006 but decreased during the 3 subsequent years. It is possible that the increase observed between 2002 and 2006 and the decline thereafter are attributable to the advent of SLT as a newer form of LTP. The introduction of a new instrument for LTP coincided with increased rates of LTP. This could have occurred because of successful marketing that suggested SLT is safer than argon LTP (ALT) and perhaps more repeatable. Eye-care specialists who purchased the laser specific to SLT would be motivated to use it, potentially in patients who have not had ALT, increasing the overall rate of trabeculoplasty. By 2006, penetration of the procedure to suitable patients could have been complete. After 2006, either there were fewer untreated patients to treat, or practitioners had become less enthusiastic about SLT's effectiveness, thereby decreasing the rate. Unfortunately, Medicare billing data do not differentiate between SLT and ALT, so we are not able to test this hypothesis directly. A possible second contributing factor to the decline in LTP use was the fact that there was an 18.6% decline in allowed charge for the pro- port, perhaps due to different definitions of glaucoma, they observed the same increase in the first half of the last decade that we observed. To our knowledge, no previous study has studied regional variation in an ophthalmic laser procedure in the United States. However, in Canada, Campbell et al 15 have examined provincial differences in the rates of LTP and reported that the increase in LTP in Canada as a whole was entirely accounted for by large increases in Ontario and British Columbia. Buys et al 16 examined whether higher physician remuneration fees in a Canadian province might in part explain an increased performance rate of trabeculoplasty but could not find a relationship. Geographic variations in preoperative glaucoma diagnostic procedures and in cataract surgery have been reported, with a magnitude similar in recent years to the 2-fold or less variation of LTP we found in those diagnosed with OAG. [7] [8] [9] [10] At the level of those undergoing glaucoma laser treatment or surgery, preoperative gonioscopy varied 2-fold in those with narrow angles or glaucoma, whereas preoperative visual field testing varied only 1.1-fold in those with OAG across regions. 10 Geographic variation in cataract surgery was analyzed at the beneficiary level. Data from 1986 and 1987 reported an 11-fold variation in cataract surgery across 181 US areas and a mean annual rate of 25.4 cataract operations per 1000 beneficiaries. 7 By 2003 through 2004, the mean rate of cataract surgery increased to 61.8 per 1000 personyears, and variation declined to 1.9-fold across the 48 contiguous states. 8 This decrease in regional variation is likely related to improved availability of the procedure over time.
The less than 2-fold regional variation of LTP and other ophthalmic procedures is at the lower end of the regional variation of most inpatient, invasive general surgical and medical procedures, which vary 1.5-to 10.1-fold across regions. [17] [18] [19] [20] [21] [22] Observed differences in regional variation across studies may be attributable to a large number of factors, including different degrees of diagnostic variation across diseases, environmental factors affecting disease severity and need for treatment, access to tertiary care providers and facilities, differing physician practice patterns, and methodologic differences in defining the study population. Many previous studies have conducted analyses using the entire aged Medicare population within a region for the denominator of the rates. In this study of regional variation in LTP rates, the variation was less at the OAG patient level (1.4-to 1.9-fold) than at the Medicare beneficiary level (1.7-to 2.9-fold). We have previously reported regional variation in glaucoma diagnosis 12 ; whether diagnostic variation would have an effect on variation in rates of procedures cannot be determined definitively from these data. However, the observation that regional variation was less when the procedure rate was expressed in terms of beneficiaries with OAG as opposed to all Medicare beneficiaries is consistent with previous studies suggesting a greater regional variability in factors influencing diagnosis, including beneficiary educational level, median income, and access to preventive care, rural clinics, and tertiary care providers, especially for conditions that are not readily apparent or easily diagnosed. 17, 18, 22 Previous studies have noted that regional variation is greater for newer procedures than for more established ones and those with a higher regional variation in procedure volume. 18, 20, 21 In some regions, the increase followed by a decrease in the LTP rate was much more dramatic than in other regions that had a more modest, monotonic increase or an increase with no subsequent decrease. These differences did not, however, lead to more uniform behavior across regions and thus have no immediate explanations from the rational analysis of practice patterns. Re-treatment after initial LTP was uncommon. Among the 92.4% of patients for whom we could identify laterality of treatment, most eyes (78.9%) received only a single LTP with no retreatment during the study period. Because Medicare claims do not differentiate between 180°and 360°procedures, a fullcircumference LTP performed over multiple time points could have been coded as multiple procedures performed on the same patient or eye, overestimating the number of LTP re-treatments. Thus, the true proportion of patients and eyes undergoing retreatment was likely to have been even lower than we reported.
The limitations of this study are those inherent in the use of the Medicare database. They include errors that may have occurred in the coding of diagnoses, eye treated, and procedures, potentially resulting in misclassification. In addition, we could not differentiate between ALT and SLT. Finally, our findings cannot be extrapolated to patients with glaucoma who are too young to be enrolled in Medicare or to those who are in Medicare health maintenance organizations.
Conclusions
The use of LTP in the aged Medicare fee-for-service population increased from 2002 through 2006 and declined from 2006 through 2009. Regional variation ranged from a 1.4-to 1.9-fold difference over time when expressed in terms of patients with OAG but was as great as 2.9-fold when conveyed in terms of Medicare beneficiaries. In all regions, only a small proportion of providers performed LTP. Re-treatment with LTP in the same eye and treatment with more than 2 LTPs in the same patient were uncommon.
